Genesis Therapeutics
PaidUnlock tough protein targets with Genesis Therapeutics’ GEMS and Pearl molecular AI.
Robotics & DevicesContact
#biotech#molecular AI#deep learning#protein targets#pharma#machine learning
About Genesis Therapeutics
Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines.
Key Features
Advanced molecular AI platform integrating deep learning and physics-based ML
Proprietary GEMS platform for AI-driven molecular design
Pearl foundation model for protein–ligand structure prediction
Reported performance exceeding AlphaFold 3 on key protein–ligand benchmarks
Focus on unlocking tough, chemically complex protein targets
Industry-leading speed with high potency and selectivity in discovery workflows
Scalable small-molecule discovery across large chemical spaces
Active internal pipeline across multiple therapeutic areas (e.g., immunology, inflammation)
Dedicated AI research advancing state-of-the-art molecular modeling
Drug pipeline development enabled by AI-guided design and triage
Best For
Medicinal chemists: Rapidly optimize potency and selectivity using AI-guided design and structure–activity insights from GEMS.Computational biologists: Predict protein–ligand structures at scale with Pearl to prioritize designs and de-risk experiments.Drug discovery teams: Unlock hard protein targets previously considered intractable to expand the addressable target space.Pharma R&D leaders: Accelerate hit finding and lead optimization to compress cycle times and improve portfolio velocity.Biotech startups: Leverage platform expertise via partnerships to build high-quality pipelines with fewer resources.Structural biologists: Generate high-confidence binding poses to inform assay design and crystallography or cryo-EM efforts.Project managers: Triage large design spaces efficiently, focusing wet-lab effort on the most promising candidates.BD and alliance teams: Structure AI-driven collaborations (e.g., with Incyte) to pursue new small-molecule programs jointly.Therapeutic area leads: Apply molecular AI to immunology and inflammation targets to advance differentiated candidates.Investors and advisors: Evaluate platform differentiation, benchmark leadership, and pipeline scalability in molecular AI.